TITLE

Risperidone: a useful adjunct for behavioural disturbance in primary cerebral tumours

AUTHOR(S)
Lee, M.; Leng, M.; Tiernan, E.
PUB. DATE
May 2001
SOURCE
Palliative Medicine;May2001, Vol. 15 Issue 3, p255
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the of patients with primary brain tumors who were administered with risperidone to treat behavioral disturbances. Clinical manifestations; Dosage and administration; Efficacy of the drug as a second line agent.
ACCESSION #
4650440

 

Related Articles

  • Extrapyramidal side effects with low-dose risperidone. Brown, E. Sherwood; Brown, E S // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p325 

    A letter to the editor is presented about the case of severe extrapyramidal symptoms and possible laryngospasm in a patient receiving low-dose risperidone.

  • Switching between clozapine and risperidone treatment. Gardner, David M.; Baldessarini, Ross J.; Benzo, José; Zarate Jr, Carlos A.; Tohen, Mauricio; Gardner, D M; Baldessarini, R J; Benzo, J; Zarate, C A Jr; Tohen, M // Canadian Journal of Psychiatry;May1997, Vol. 42 Issue 4, p430 

    A letter to the editor which examines the outcome of the coadministration of clozapine and risperidone is presented.

  • Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Friedlander, Robin; Lazar, Susan; Klancnik, Joseph; Friedlander, R; Lazar, S; Klancnik, J // Canadian Journal of Psychiatry;Oct2001, Vol. 46 Issue 8, p741 

    Objective: To study the usage, efficacy, and side effects patterns of atypical neuroleptics (atypicals) in adolescents and young adults with developmental disabilities (DDs) (mental retardation). Method: We undertook a chart review of adolescents and young adults (under...

  • Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Chue, Pierre; Welch, Ron; Binder, Carin // Canadian Journal of Psychiatry;Oct2004, Vol. 49 Issue 10, p701 

    Objective: To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder.Method: Ten patients stable for at least 10 days on monotherapy with oral...

  • Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. Johnsen, Erik; A.^Kroken, Rune; Wentzel-Larsen, Tore; A.^Jørgensen, Hugo // BMC Psychiatry;2010, Vol. 10, p26 

    Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards...

  • Increased mortality among elderly patients with dementia using atypical antipsychotics. Singh, Sonal; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p252 

    Discusses research being done on the use of atypical anti-psychotic drugs in the treatment of behavioral and psychological symptoms of dementia. Reference to a study by P. E. Lee, S. S. Freedman et al, published in the 2004 issue of the "British Medical Journal"; Incidence of death among...

  • Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders. Hummel; Dittmann; Forsthoff; Matzner; Amann; Grunze // Neuropsychobiology;2002 Supplement 1, Vol. 45, p37 

    Atypical neuroleptics are increasingly used in the treatment of bipolar and schizoaffective disorders. Currently, numerous controlled short-term studies are available for clozapine, olanzapine, risperidone or quetiapine, but long-term data are still missing. Three patients (2 with bipolar...

  • Correlation of qEEG with PET in Schizophrenia. Alper, Kenneth; Günther, Wilfred; Prichep, Leslie S.; John, E. Roy; Brodie, Jonathan // Neuropsychobiology;1998, Vol. 38 Issue 1, p50 

    PET relative metabolism was correlated with quantitative EEG in 9 schizophrenic patients. The PET metabolic regions of interest were the frontal lobes, thalamus and basal ganglia, and right and left temporal lobes. Significant positive correlations were seen for the frontal lobes and delta EEG...

  • Haloperidol.  // AHFS Consumer Medication Information;Sep2020, p1 

    Haloperidol is used to treat psychotic disorders (conditions that cause difficulty telling the difference between things or ideas that are real and things or ideas that are not real). Haloperidol is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics